孟鲁司特钠辅助治疗儿童支气管哮喘用药临床疗效观察

Clinical eff icacy of montelukast associated with Seretid on asthma children

目的探讨白三烯受体拮抗剂孟鲁司特钠在儿童哮喘辅助治疗中的作用,以及用药疗程的长短。方法将48例确诊为轻、中度哮喘的患儿按2∶1比例随机分为治疗组32例、对照组16例,治疗组在吸入舒利迭基础上,加用孟鲁司特钠口服,足量用药3个月,再逐渐减量3个月,停药后随诊6个月。观察哮喘临床控制、复发情况及肺功能变化。结果临床控制率、肺功能改善率,治疗组明显高于对照组;复发率,治疗组明显低于对照组。结论孟鲁司特钠辅助治疗儿童哮喘有效,随着疗程的增加,疗效越来越明显,复发率也越来越低。

Objective To evaluate the clinical efficacy ofmontelukast on asthma children. Methods A total of 48 children with asthma were randomly divided into two groups;montelukast group （group A） and Seretid group （group B）. 32 children in group A were treated with montelukast and Seretid lot 3 month,and 16 children in group B were treated with only Seretid for 3 month. Results There was significant amelioration concerning the clinical efficacy rates and lung function efficacy rates,respectively,without serious cases in both groups and also no statistically significant difference between them （P〉0.05）. Conclusion Montelukast is a effective drug in treating childrenwith asthma and possesses reliable efficacy and less adverse reaction. Montelukast associated with Seretid can be used to treat asthma effectively.